United States

Almirall SA (ALM.MC)

ALM.MC on Madrid SE C.A.T.S.

21 Feb 2017
Change (% chg)

-- (--)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low


Chart for ALM.MC


Almirall SA is a Spain-based company principally engaged in the pharmaceuticals manufacture. The Company focuses on development and marketing of drugs applied in various therapeutic areas, such as nervous system, gastrointestinal, dermatological, respiratory system, antiinfectives, as well as antineoplastic and immunomodulating... (more)


Beta: 0.27
Market Cap(Mil.): €2,708.42
Shares Outstanding(Mil.): 172.95
Dividend: 0.19
Yield (%): 1.21


  ALM.MC Industry Sector
P/E (TTM): 16.30 28.39 29.32
EPS (TTM): 0.96 -- --
ROI: 7.15 13.54 13.03
ROE: 11.34 14.43 14.17

BRIEF-Almirall reaches agreement with employees for restructuring in Spain

* Says reaches agreement to implement restructuring plan in Spain, reduces to 102 from 121 a number of employees affected

Nov 24 2016

BRIEF-Almirall reports 9-month net profit up 41 percent

* Reports 9-month EBITDA up 6.5 percent at 183.8 million euros ($203.4 million) versus 172.6 million euros year ago

Nov 07 2016

BRIEF-Almirall presents restructuring plan affecting 121 jobs

* Presents restructuring plan in Spain affecting up to 121 jobs

Oct 18 2016

BRIEF-Almirall announces data from pivotal phase-3 clinical trials with inhibitor to treat psoriasis

* Announces results from two pivotal phase-3 clinical trials (reSURFACE 1 and 2) achieving primary endpoint of Tildrakizumab, an investigational IL-23p19 inhibitor, in patients with moderate-to-severe plaque psoriasis Source text for Eikon:

Oct 03 2016

BRIEF-Almirall announces positive phase III results for drug against psoriasis

* Announces positive results from the phase III trial showing efficacy of dimethyl fumarate, a new systemic oral drug for patients with chronic plaque psoriasis

Sep 28 2016

More From Around the Web

Earnings vs. Estimates